DA
daratumumab (Darzquro / Dalinvi / Darzalex)
Johnson & Johnson Services, Inc. · CD38 · Monoclonal Antibodies
Status
✓ Approved
Indications
15 conditions
Clinical Trials
357 total
Active Trials
209 ongoing
Targets
CD38
What is daratumumab?
Last updated: February 2025daratumumab is a monoclonal antibodies developed by Johnson & Johnson Services, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.
Drug Profile
| Generic Name | daratumumab |
| Brand Names | Darzquro, Dalinvi, Darzalex |
| Company | Johnson & Johnson Services, Inc. |
| Drug Class | Monoclonal Antibodies, Antibody |
| Molecular Target | CD38 |
| Route | Injectable (Others), Intravenous (IV), Subcutaneous Injection |
| Status | Approved |
Mechanism of Action
Molecular Targets
daratumumab acts on 1 molecular target:
| CD38 | CD38 molecule (ADPRC1, ADPRC 1) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Clinical Trials
There are currently 357 clinical trials registered, with 209 actively ongoing.
| Trial ID | Phase | Title | Status |
|---|---|---|---|
| NCT03899155 | Phase 2 | Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Tr | ● Recruiting |
| NCT06083922 | Phase 2 | A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patien | ● Recruiting |
| NCT06169215 | Phase 2 | A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk N | ● Active Not Recruiting |
| NCT07234019 | Phase 2 | A Randomized, Open-label Study To Compare The Efficacy And Safety Of Rituximab Combining Anti-CD38 M | ● Recruiting |
| NCT07297563 | Phase 2 | A Randomized, Open-label Study To Compare The Efficacy And Safety Of Anti-CD38 Monoclonal Antibody V | ● Recruiting |
| NCT06948084 | Phase 2 | A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse Wi | ● Not Yet Recruiting |
+353 more trials available with free account
Sign up free to view all clinical trials →Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.
Therapeutic Indications
daratumumab is developed for 15 unique indications across 2 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Plasma cell myeloma | ✓ Approved |
| Immune system disorders | Primary amyloidosis | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Diffuse large B-cell lymphoma | Phase II |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-Hodgkin's lymphoma | Phase II |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Mantle cell lymphoma | Phase II |
+10 more indications available with free account
Sign up free to view all indications →